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Abdominal aortic aneurysm (AAA) is an important cause of death in older adults which has no 
current drug therapy. Inflammation and abnormal redox status are believed to be key 
pathogenic mechanisms for AAA.  In light of evidence correlating inflammation with aberrant 
fatty acid profiles, this study compared erythrocyte fatty acid content in 43 AAA patients 
(diameter 3.0-4.5 cm) and 52 healthy controls. In addition, the effect of omega-3 
polyunsaturated fatty acid (n-3 PUFA) supplementation on erythrocyte fatty acid content was 
examined in a cohort of 30 AAA patients as part of a 12-week randomised placebo-controlled 
clinical trial.  Blood analyses identified associations between AAA and decreased linoleic acid, 
and AAA and increased ∆6-desaturase activity and biosynthesis of arachidonic acid from 
linoleic acid. n-3 PUFA supplementation (1.5g DHA+0.3g EPA/day) decreased red blood cell 
distribution width (RDW, 14.8±0.4% to 13.8±0.2%, p=0.003) and levels of pro-inflammatory 
n-6 PUFAs (arachidonic acid, 12.46±0.23% to 10.14±0.3%, P<0.001; adrenic acid 2.12±0.13% 
to 1.23±0.09%, p<0.001).  In addition, Δ-4 desaturase activity increased 
(docosahexaenoic/docosapentaenoic acid ratio, 1.85±0.14 to 3.93±0.17, P<0.001) and elongase 
2/5 activity decreased (adrenic acid/arachidonic acid ratio, 0.17±0.01 to 0.12±0.01, P<0.01) 
following supplementation.  The findings suggest n-3 PUFAs improve fatty acid profiles and 
ameliorate factors associated with inflammation in AAA patients. 
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Abdominal aortic aneurysm (AAA) is a full-thickness dilation of the infrarenal aorta that can 
lead to lethal artery rupture (1). The global prevalence of AAA in adults over the age of 65 y is 
estimated to be between 1 and 3% (2).  While chronic aortic inflammation, oxidative stress and 
enhanced proteolytic enzyme activity are implicated in the destructive remodelling of aortic 
connective tissue that occurs in AAA, (3, 4),  no recognised drug therapies exist to halt or 
reverse these aberrant molecular processes or their injurious mechanical sequelae.   
 
Technical advances in mass spectrometry methods have resulted in the availability of tools to 
accurately profile the human lipidome (5) and, more specifically, quantify the accumulation of 
omega-3 polyunsaturated fatty acids (n-3 PUFAs) in red blood cell membranes.  Animal data 
have suggested the potential of n-3 PUFA supplementation to limit small AAA growth through 
positive impacts on oxidative stress status (6, 7) and interference with inflammatory cascades 
(8-10). While clinical evidence in AAA patients is limited, low serum eicosapentaenoic acid 
(EPA) levels have been reported to be associated with larger aneurysm size and faster growth 
rate in a Japanese patient population (11).  A separate study involving a Danish cohort of 
patients, however, found no association between n-3 PUFA blood status and the development 
or growth of AAA (12).  n-3 PUFA blood status is typically evaluated by omega-3 index 
measurement (13).  The omega-3 index represents the ratio of EPA + docosahexaenoic acid 
(DHA) to all other fatty acids incorporated in red blood cell membrane phospholipids and 
substantial published research suggests that this measurement is a reliable predictor of 
cardiovascular event risk (14-17).  In light of this, and evidence correlating specific disease 
states with distinct fatty acid profiles (18-20), the present study was designed to compare full 
blood count data, baseline omega-3 index values and fatty acid profiles of erythrocytes obtained 
from AAA patients with those of a healthy control cohort as part of an ongoing clinical trial.  
In addition, the impact of physiologically appropriate n-3 PUFA supplementation on full blood 
count values, the omega-3 index and erythrocyte membrane fatty acid composition was 
examined in a cohort of AAA patients as part of a 12-week randomised, double-blind, placebo-










controlled clinical trial.  It was hypothesised that comparative analysis of erythrocyte fatty acid 
composition would yield a distinct AAA fatty acid profile that could direct future progress 


































Materials and Methods  
 
Observational (case-control) study  
AAA patients were recruited from the Sunshine Coast University Hospital and a private clinic 
(Sunshine Vascular) and healthy control participants were recruited from the general population 
of the Sunshine Coast, Queensland with approval from the University of the Sunshine Coast 
(A/13/473 and A/16/833) and the Prince Charles Hospital Human Research Ethics Committees 
(HREC/16/QPCH/114 and HREC/12/QPCH/13). The patient group included 43 men with 
small AAA (diameter 3.0-4.5 cm) and the control group included 52 men without a documented 
AAA.  It has previously been reported that there are significant differences in omega-3 index 
between men and women (21), and AAA is known to be much more common in men than 
women (22).  In view of this, only men were included in the current study.  Written informed 
consent was obtained for each participant.  Maximum AAA diameter was measured by 
ultrasound prior to study entry.  Exclusion criteria included age below 60 or above 86 years, 
body mass index (BMI) above 39 kg∙m-2, uncontrolled hypertension, cardiac arrhythmia, heart 
failure, symptomatic aortic stenosis, chronic obstructive pulmonary disease, chronic 
inflammatory disease and regular use of prescription anti-inflammatory medication.  A family 
history of AAA or known aneurysmal disease served as additional exclusion criteria for control 
participants.  All participants refrained from non-prescribed anti-inflammatory medications 72 
h prior to blood collection and abstained from alcohol and caffeine for the 12 h leading up to 
their study visit.     
   
Omega-3 clinical trial 
The impact of n-3 PUFA supplementation on erythrocyte fatty acid composition was 
investigated in AAA patients as part of a parallel-design, double-blind, placebo-controlled trial 
(ANZCTR12616000483459), carried out between June 2017 and June 2018. Patients with 
small (3.0 - 4.9 cm) AAA (n=32) were recruited from Nambour General Hospital, Sunshine 










Coast University Hospital and a private clinic (Sunshine Vascular) and randomised (Figure 1) 
to receive either 1) active fatty acids (3 Blackmores Omega Brain capsules each containing 500 
mg DHA and 100 mg EPA and delivering a total of 1.8 g n-3 PUFAs per day) or 2) placebo 
fatty acids (3 capsules each containing 490 mg corn oil, 490 mg olive oil and 20 mg fish oil) 
for a period of 12 weeks.  Capsules were of similar appearance and flavour. Participants were 
supplied with capsules at day 0, week 3 and week 8, with instruction to take three each morning. 
The final study visit was at week 12. A substantial research literature suggests the intervention 
dose and duration selected for the clinical trial will be sufficient to raise the omega-3 index of 
supplemented subjects to protective levels associated with positive cardiovascular outcomes 
(23, 24). Exclusion criteria for the clinical trial were: age below 55 or above 86 years, 
consumption of three or more fish meals per week, the use of fish oil or krill oil supplements 
and the use of anti-inflammatory medications.  Written informed consent was obtained from 
each participant and information regarding medical history, physical activity and dietary intake 
of n-3 PUFAs was collected. The protocol was approved by the University of the Sunshine 
Coast (Ethics Approval Number A/16/833) and the Prince Charles Hospital Human Research 
Ethics Committees (HREC/16/QPCH/114).   The study was conducted in accordance with the 
Declaration of Helsinki (1964). 
 
Randomisation and evaluation of compliance 
An Excel block randomisation algorithm was used to assign participants to either an active or 
a placebo treatment protocol.   Random selection of block size 4 or 6 during the computerised 
sort avoided selection bias (25).  Sequentially numbered containers were used to implement the 
random allocation of capsules. The randomisation allocation sequence was generated by the 
corresponding author.  Compliance with treatment protocols was evaluated by monitoring 
capsule returns and by gas chromatography-mass spectrometry (GC-MS) measurement of red 
blood cell omega-3 index.  
 
  










Blood sample collection 
Fasting blood samples were collected from AAA patients and healthy control participants into 
EDTA-containing tubes and serum separator tubes.  Erythrocytes from EDTA tubes were 
sedimented by centrifugation (1500 x g, 15 min, 15°C), the plasma and buffy coat fractions 
were removed and the packed red blood cells were stored at -80°C until analysis.  Blood 
collected into serum separator tubes was allowed to clot at 22 ° C for 30 min prior to 
centrifugation (1500 x g, 15 min, 15°C).  The serum was collected and centrifuged (4000 x g, 
5 min, 4°C) and the supernatant was stored at -80°C until processing and analysis.  For the 
omega-3 clinical trial, fasted blood samples were collected from AAA patients at day 0 (prior 
to initiation of the study), at day 21 (following 3 weeks of supplementation) and at day 84 
(following 12 weeks of supplementation).  Erythrocytes from EDTA tubes were processed and 
stored as described above.   
 
Erythrocyte fatty acid analysis 
Choice of erythrocytes as the preferred matrix for assessment of n-3 PUFA status was based on 
evidence suggesting 1) measurement of erythrocyte fatty acid levels assesses long-term dietary 
fatty acid intake, 2) erythrocyte fatty acid levels are less sensitive than plasma to day-to-day n-
3 PUFA intake, 3) erythrocyte n-3 PUFA levels display one-fourth of the within-person 
variability that occurs with plasma and 4) erythrocyte n-3 PUFA levels are highly correlated 
with those in a variety of tissues (26).  Erythrocyte fatty acid composition was determined using 
GC-MS as previously described (27). Briefly, a 600 μl aliquot of methanol containing butylated 
hydroxytoluene (BHT; 20 mg/100 ml) as an antioxidant was added to erythrocyte samples (300 
μl).  The cells were homogenised with glass rods (1 min), flushed with nitrogen gas and 
incubated on ice for 30 min.  A 600 𝜇l aliquot of chloroform was added to the suspension and 
cells were homogenised, flushed and incubated as before.  The preparation was centrifuged 
(3000 x g, 4°C, 5 min) and the supernatant was withdrawn, flushed with nitrogen gas and stored 
on ice.  This procedure was repeated twice with 300 μ l volumes of methanol/BHT and 










chloroform and incubation periods of 10 min.  In a final extraction step, 1 ml of pooled lipid 
supernatant was combined with chloroform (800 μl) and KCl (0.05M; 460 μl), the solution was 
mixed by vortex, flushed with nitrogen gas and centrifuged (3000 x g, 4°C, 10 min).  The 
supernatant was discarded and the fraction containing lipids was dried under nitrogen gas.  The 
extracted lipids were hydrolysed in the presence of 500 μl of 9M HCl:H2O:acetonitrile (1:1:18 
containing 25 mg/50 ml BHT) during overnight incubation at 65°C.  The hydrolysed samples 
were dried under nitrogen gas and, following a 10 min incubation at -80°C, were freeze-dried 
(Thermo Savant Modulyo Freeze Dryer System, Thermo Fisher Scientific) for 30 min.  Samples 
were derivatised in 250 μl of hexane containing 10 μl 1-tert-butyldimethylsilylimidazole during 
a 2h incubation at 37°C.  Fatty acids were separated and analysed with a Perkin Elmer Clarus 
580 gas chromatograph coupled to a Perkin Elmer Clarus SQ85 mass spectrometer using a 
Perkin Elmer Elite 5MS column (30m x 0.25 mm ID x 0.25 mm film).  The GC method included 
a split ratio of 30:1 with injector at 300°C and temperature programming of 170°C (initial) 
ramped to 310°C at a rate of 6°C/min followed by a 5 min hold period.  The MS method 
included ionisation at 70 eV with a scan range of 45-450 m/z for 4.0-28.3 min.  Peaks were 
identified by comparison with known standards or the National Institute of Standard and 
Technology Library (NIST 2008 Library).  Omega-3 indices were expressed as the combined 




Product to precursor erythrocyte phospholipid fatty acid ratios served as indices of activity 
levels of enzymes involved in fatty acid metabolism.  The index of Δ-9 desaturase activity was 
calculated as the ratio of oleic acid to stearic acid (28) and the index of Δ-4 desaturase activity 
was calculated as the ratio of docosahexaenoic acid (DHA) to docosapentaenoic acid (DPA) 
(29).  The index of Δ-6 desaturase was calculated in two ways a) as a ratio of dihomo-𝛾-
linolenic acid to linoleic acid (29) (this calculation includes the activities of the enzymes Δ-6 










desaturase and elongase 5) and b) as a ratio of 𝛾-linolenic acid to linoleic acid (28) (this 
calculation includes the activity of Δ-6 desaturase only).  The ratio of arachidonic acid (AA) to 
linoleic acid (LA) served as an index of desaturase/elongase-mediated LA → AA biosynthesis 
(30).  The index of stearoyl-CoA desaturase activity was calculated as the ratio of palmitoleic 
acid to palmitic acid (29) and the index of elongase 2/5 activity was calculated as the ratio of 
adrenic acid to AA (31). 
 
Full blood count analysis 
Whole blood from fasted participants was collected into EDTA tubes and full blood count 
analyses were conducted within 10 min of the collection using a Coulter AC∙T diff™.  Data 
regarding red blood cell indices (haemoglobin, HgB; haematocrit, Hct; mean corpuscular 
volume, MCV; mean corpuscular haemoglobin, MCH; mean corpuscular haemoglobin 
concentration, MCHC; red blood cell distribution width, RDW), white blood cell counts 
(lymphocytes, monocytes, granulocytes) and platelet counts and indices (mean platelet volume, 
MPV; plateletcrit, Pct; platelet distribution width, PDW) were collected.  Instrument calibration 




Observational (case-control) study  
Erythrocyte fatty acid content and full blood count analysis have not been investigated 
previously in small AAA and healthy control participants. Group size estimates for the 
observational study were based on RDW values reported in healthy controls (RDW, 13.1±1.3, 
n=40) and patients with coronary artery ectasia (RDW, 14.8±1.6, n=54) (32). A group size 
estimate of 14 was calculated with 85% power (alpha level of 0.05) using power/sample size 
(Univ. British Columbia) and pooled variance (Solvers statistics) calculators. 
 
  










Omega-3 clinical trial 
The group size estimate for the omega-3 clinical trial was based on fatty acid values obtained 
from a 5-month omega-3 fatty acid supplementation trial (1.8 g/day) in a healthy cohort (33). 
Baseline erythrocyte levels (n=23) were: arachidonic acid (16.1±1.2%), adrenic acid 
(4.1±0.5%), EPA (0.5±0.4%) and DHA (3.9±0.8%). End-of-study levels (n=24) were: 
arachidonic acid (13.6±1.2%), adrenic acid (2.6±0.5%), EPA (2.5±0.4%) and DHA 
(7.0±0.8%).  Group size estimates were between 1 and 4 (85% power; alpha level of 0.05). 
 
Continuous demographic data for AAA patients and control participants were compared using 
a student’s t-test and are presented as mean±SD.  Categorical demographic variables were 
compared using a Fisher’s exact test.  Experimental data are presented as mean±SEM and 
between group differences were examined by student’s t-test analysis.  The association between 
independent variables identified as being significantly different (see Table 8) and AAA was 
assessed using linear regression analysis with adjustment for covariates shown to be 
imbalanced between groups (hypertension, diabetes mellitus, coronary heart disease, 
dyslipidaemia, use of statins or low-dose aspirin, current and previous smoking history, and 
age).  All variables were introduced in one step in order of decreasing tolerance.   Data were 
analysed with Prism (GraphPad Software, La Jolla, CA).  IBM SPSS Statistics Version 24 was 





















Observational (case-control) study  
 
Baseline characteristics 
Baseline characteristics of the case-control study are shown in Table 1.  AAA patients were 
older and were characterised by a higher prevalence of hypertension, diabetes mellitus, 
dyslipidaemia, CHD and smoking history.  AAA patients were more commonly prescribed 
statins and anti-platelet drugs. 
 
Fatty acid methyl ester analysis 
Twenty-three fatty acid methyl esters were consistently identified in erythrocyte membranes 
obtained from AAA patients and healthy control participants (Supplemental Table S1). 
 
Erythrocyte fatty acid profiles 
Mean omega-3 index values were similar in cases and controls while the mean omega-6:omega-
3 (n-6/n-3) ratio was significantly lower than the corresponding value obtained for the control 
cohort (p=0.047; Table 2).  Levels of the saturated fatty acid margaric acid (C17:0) were 
significantly higher in AAA patients compared to healthy control participants (p=0.007) while 
levels of the n-6 fatty acid, linoleic acid (C18:2) were significantly lower (p=0.007).  The n-3 
PUFA, DPA (C22:5) was significantly higher in erythrocytes from AAA patients compared to 
control participants (p<0.001).   Data was adjusted for hypertension, diabetes mellitus, coronary 















The indices of Δ-4 (DPA→DHA) and Δ-9 desaturase (stearic→oleic) activity in erythrocytes 
from AAA patients were comparable to the control cohort (Table 3) as were the index of 
stearoyl-CoA desaturase (palmitic→palmitoleic acid) activity and the index of elongase 2/5 
(AA→adrenic acid) activity.  The index of Δ-6 desaturase (1) activity was significantly higher 
in erythrocytes from AAA patients compared to control participants (p=0.005), as was the index 
of desaturase/elongase-mediated LA → AA biosynthesis (p=0.008).  Data was adjusted for 
hypertension, diabetes mellitus, coronary heart disease, low-dose aspirin and statin use, active 
or previous smoking history and age (Table 8).   
 
Red blood cell indices, white blood cell counts and platelet counts and indices 
Red blood cell distribution width and other red blood cell indices were similar in cases and 
controls, as were white blood cell counts and platelet counts and indices following adjustment 
for covariates shown to be imbalanced between groups (Table 4).  
 
Omega-3 clinical trial 
 
Baseline characteristics 
Baseline characteristics were similar between groups with the exception of statin use (Table 1). 
 
Participant compliance and tolerability 
A high level of adherence to supplement intake was identified by return capsule counts 
(Placebo: 96.4±1.2, 96.8±2.1, and 95.0±2.9% at Weeks 3, 8 and 12, respectively; omega-3 fatty 
acid group: 97.2±0.9%, 94.0±1.7% and 95.0±1.6% at Weeks 3, 8 and 12, respectively). This 
was supported by GC-MS analysis of fatty acid incorporation in red blood cell membrane 
phospholipids.  The omega-3 index was markedly increased in all participants in the omega-3 
fatty acid group over the 12-week trial period (Table 5).   No change in omega-3 index was 
observed in participants who were randomised to receive placebo capsules.  Two participants 










in the placebo group withdrew from the trial citing gastrointestinal disturbances (Figure 1).  
Among participants who completed the 12-week trial, three in the placebo group reported 
burping, with one of these also experiencing nausea.  In the omega-3 fatty acid group, three 
participants reported burping or reflux, and one participant reported flatulence.  
 
Erythrocyte fatty acid profiles in AAA patients following n-3 PUFA supplementation 
Significant increases in DHA (76%, p<0.001) and EPA (69%, p<0.001) levels were observed 
in erythrocytes from AAA patients following 12 weeks of n-3 PUFA supplementation (Table 
5).  This effect was accompanied by significant decreases in the n-6 fatty acids arachidonic acid 
(AA, C20:4, p<0.001), adrenic acid (C22:4, p<0.001) and dihomo-γ-linolenic acid (C20:3, 
p=0.003) from baseline to week 12.  Additional fatty acids altered by n-3 PUFA 
supplementation included the n-3 PUFA docosapentaenoic acid (DPA, C22:5) and the very 
long chain fatty acid nervonic acid (C24:1), both of which decreased at week 12 (p=0.004 and 
p=0.009 respectively).  The mean omega-3 index value among AAA patients increased at week 
3 (33%, p<0.001) and week 12 (74%, p<0.001) while the mean n-6/n-3 ratio decreased at these 
time points (22%, p<0.001 and 42%, p<0.001 respectively).  No changes in any fatty acid levels 
were observed for the placebo group from baseline to week 3 or from baseline to week 12. 
 
Enzyme activity 
Twelve-week n-3 PUFA supplementation significantly increased the index of Δ-4 desaturase 
(DPA→DHA) activity in erythrocytes from AAA patients (p<0.001) while the index of Δ-6 
desaturase (LA→DGLA and LA→GLA) activity, the index of Δ-9 desaturase (stearic→oleic) 
activity and the index of stearoyl-CoA desaturase (palmitic → palmitoleic acid) activity 
remained unchanged (Table 6).  Omega-3 PUFA supplementation of AAA patients lowered the 
index of desaturase/elongase-mediated LA → AA biosynthesis and the index of elongase 2/5 
(AA→adrenic acid) activity to levels that were comparable to the control cohort (p=0.031 and 










p=0.002 respectively).  No changes in any enzyme activity levels were observed for the placebo 
cohort. 
Omega-3 fatty acid supplementation decreases red blood cell distribution width 
Significant decreases in red blood cell distribution width (p=0.003), red blood cell counts 
(p=0.019), haematocrit percentage (p=0.016), platelet counts (p=0.042) and plateletcrit 
percentage (p=0.021) were observed for AAA patients following 12 weeks of n-3 PUFA 
































Observational (case-control) study 
Analysis of erythrocyte fatty acid profiles among AAA patients highlighted a mean omega-3 
index value that was comparable to the control cohort in conjunction with an n-6/n-3 fatty acid 
ratio that was significantly lower.  Among individual fatty acids measured, levels of the 
saturated fatty acid margaric acid and the omega-3 fatty acid DPA were significantly higher in 
erythrocytes from AAA patients and levels of the omega-6 fatty acid linoleic acid were 
significantly lower compared to control.  The lower levels of linoleic acid in conjunction with 
higher levels of adrenic acid in the AAA cohort are of note.  A meta-analysis of prospective 
cohort studies (n=310,602 participants, n=12,479 cases) indicated that highest levels of dietary 
linoleic acid intake were associated with a 15% lower risk of CHD events and a 21% lower risk 
of CHD deaths when compared to lowest levels of linoleic acid intake (34).  In addition, a 
higher level of circulating linoleic acid in a community-based US cohort (n=2,792) was 
associated with lower total mortality risk (extreme-quintile hazard ratio=0.87; P=0.005) and a 
lower risk of cardiovascular disease mortality (22% lower risk in the highest versus the lowest 
quintile; P=0.02) (35).  It has been suggested that the observed cardio-protective effects of 
linoleic acid are related to its competition with pro-inflammatory arachidonic acid for re-
acylation into membrane phospholipids (36).  In line with this, a strong inverse association has 
been reported between serum linoleic acid levels and high-sensitivity C-reactive protein 
(hsCRP), a key marker of inflammation (37).  These findings suggest that the altered n-6 fatty 
acid profile in AAA skews cellular responses toward pro-inflammatory eicosanoid production 
and upregulated inflammatory pathways.  
 
Desaturase enzymes catalyse the rate-limiting steps in long chain fatty acid synthetic pathways 
and their activities influence erythrocyte phospholipid fatty acid composition (28).  In this 
study, Δ-4 and Δ-9 desaturase activity levels in erythrocytes from AAA patients were 
comparable to those of a healthy control cohort.  In contrast, the index of desaturase/elongase-










mediated LA → AA biosynthesis was significantly higher in erythrocytes from AAA patients 
compared to control participants, as was the index of Δ-6 desaturase activity.  The higher index 
of Δ-6 desaturase activity suggests anti-inflammatory n-3 PUFA formation is repressed in 
favour of pro-inflammatory n-6 PUFA biosynthesis.  It is of note that the higher index of 
desaturase/elongase-mediated LA → AA biosynthesis did not translate into higher levels of 
arachidonic acid in this cohort.  Arachidonic acid is a known substrate for inflammatory 
eicosanoid synthesis and, while it is possible that the absence of an increase in arachidonic acid 
levels in AAA patients may be due to excessive shunting of this fatty acid to an alternative 
eicosanoid biosynthetic pathway, we have previously reported lower levels of prostaglandin E2 
(a product of arachidonic acid metabolism) in this AAA cohort compared to healthy control 
participants.  It is thus possible that the higher conversion of LA to AA in AAA patients led to 
increased flux through the n-6 biosynthetic pathway beyond arachidonic acid to adrenic acid 
resulting in the observed higher levels of the latter.  The anomalies observed in enzyme activity 
indices among AAA patients suggest a predisposition toward reactions that favour increased 
production of n-6 PUFAs with high pro-inflammatory potential and repressed production of 
their anti-inflammatory n-3 PUFA counterparts. 
 
Omega-3 clinical trial 
Twelve-week n-3 PUFA supplementation decreased levels of the n-6 fatty acids arachidonic 
acid and adrenic acid and increased levels of the n-3 fatty acids DHA and EPA in AAA patient 
erythrocytes while concomitantly raising the mean omega-3 index to a value almost double that 
at study entry (8.03%).  Importantly, the post-supplementation omega-3 index value was within 
the 8-12% range that affords cardioprotection (26).  The large reduction in arachidonic and 
adrenic acid levels with n-3 PUFA supplementation likely reflects competition of DHA and 
EPA for incorporation into existing erythrocyte membranes and/or greater availability of n-3 
PUFAs for integration into newly synthesised membranes (38).  The anti-inflammatory and 
immunomodulatory properties of increased cellular phospholipid EPA and DHA levels are 
likely to favourably impact AAA disease.  Higher n-3 PUFA intake results in partial 










substitution of arachidonic acid for EPA and DHA, a net decrease in pro-inflammatory 
eicosanoid production and favourable impacts on inflammatory responses (39). The latter is 
due to competition of n-3 PUFAs with arachidonic acid for the same metabolic enzymes 
resulting in production of an alternate series of less biologically potent eicosanoids with weaker 
pro-inflammatory, platelet-aggregating and vasoconstrictive activities (39-41).  Omega-3 
PUFAs are, in addition, substrates of cytochrome P450 enzymes and increasing the levels of 
these fatty acids results in enhanced production of DHA- and EPA-derived metabolites at the 
expense of arachidonic acid-derived metabolite production (42).  The lower n-6/n-3 ratio, a 
value reflecting the balance between precursor PUFAs giving rise to downstream pro- and anti-
inflammatory eicosanoids respectively, supports an n-3 PUFA-driven switch towards a more 
favourable eicosanoid profile.  
 
Twelve-week n-3 PUFA supplementation significantly increased the index of Δ-4 desaturase 
activity in erythrocytes from AAA patients and lowered the index of desaturase/elongase-
mediated LA → AA biosynthesis and the index of elongase 2/5 activity to levels that were 
comparable to the control cohort (Supplemental Figure S1).  The index of Δ-6 desaturase 
activity was unaffected by n-3 PUFA supplementation.  Δ-4 Desaturase and Δ-6 desaturase 
each form part of a distinct biochemical pathway that yields DHA as a biosynthetic product.  
Δ-6 Desaturase forms part of a coupled microsomal-peroxisomal pathway that produces DHA 
through sequential desaturations and elongations, while Δ-4 desaturase forms part of an 
alternative pathway that yields DHA through a single Δ4 desaturation step (43).  As expected 
with DHA supplementation, the ratio of DHA:DPA increased.  Determination of the 
contribution of Δ-4 desaturase, if any, to this result would require direct measurement of the 
activity of this enzyme. The decreases in enzyme activities leading to pro-inflammatory n-6 
PUFA production suggest n-3 PUFA supplementation alters fatty acid metabolism in a manner 
that is likely to improve the inflammatory status of AAA patients.  
  










Twelve-week supplementation with n-3 PUFAs (1.8g/d) significantly decreased RDW, red 
blood cell counts, haematocrit percentage and platelet count and platelet percentage in AAA 
patients.  RDW is a numerical measure reflecting size variability or heterogeneity of volume 
among circulating erythrocytes (44).  It is well documented that RDW correlates with 
inflammatory biomarkers in a multitude of clinical settings (45-47) and a large cohort study has 
supported the existence of a strong graded relationship between RDW and high sensitivity C-
Reactive Protein and RDW and erythrocyte sedimentation rate, independent of confounding 
factors (48).  In light of this and evidence suggesting the existence of extensive cross-talk 
between the pathways of inflammation and coagulation (49, 50), it is likely that the observed 
changes reflect n-3 PUFA-mediated improvements in inflammatory status in AAA patients who 
received this supplement. 
 
The study, while limited by small sample size, was characterised by multiple strengths that 
included a placebo-controlled, double-blind study design and use of a validated biomarker of 
erythrocyte membrane fatty acid content.  Although it is clear that n-3 PUFA supplementation 
improves fatty acid status among AAA patients, further studies will be required to determine 
whether this improvement translates into positive alterations in the histopathologic appearance 
of AAA disease at the level of the aorta.  In addition, while an aberrant fatty acid profile was 
observed in AAA patients compared to healthy control participants, it is not yet known why 
this occurs.  It is possible that expression of fatty acid metabolising enzymes is dysregulated in 
AAA patients, resulting in the observed aberrant profile of enzyme activity and erythrocyte 
fatty acid proportions.  It is noteworthy that participants were screened at entry for dietary 
intake of fish and seafood, with all participants consuming no more than two oily fish meals 
per week.  It is therefore unlikely that the observed differences in fatty acid profile are attributed 
to differences in diet between the two cohorts. 
 
Taken together, the results presented here indicate that erythrocytes from AAA patients 
demonstrate a distinct fatty acid profile that is characterised by aberrant proportions of n-6 fatty 










acids with high inflammatory potential while full blood count parameters among these patients 
are characterised by alterations that reflect the influence of systemic inflammation and 
oxidative stress.  Improvements in inflammatory parameters and n-6 fatty acid status following 
n-3 PUFA supplementation suggest dietary fatty acids represent a viable therapeutic 
intervention in AAA. 
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Table 1: Demographic, biometric and medical characteristics of AAA patients and control 
participants. Continuous demographic data are presented as mean ±  SD, categorical 
demographic data are presented as number (percentage).    



























Age (years)  
 
71.2 ± 5.9 74.6 ± 5.6 * 73.6 ± 5.0 75.1 ± 5.7 
AAA size (mm) 
 
 38.8 ± 5.4 39.3 ± 5.7 39.2 ± 5.0 
Smoking: 
    Never                          
    Past                                                                                       


















BMI (kg/m2)  
 
25.9 ± 4.2 28.6 ± 4.8 29.4 ± 4.1 29.0 ± 5.0 
SBP (mmHg)  
 
137.3 ± 13.9 137.9 ± 16.2 135.8 ± 16.3 144.0 ± 19.6 
DBP (mmHg)  
 
79.3 ± 8.2 78.2 ± 8.8 77.6 ± 7.6 80.0 ± 10.7 
Hypertension  
 
20 (38%) 27 (63%) † 6 (40%) 11 (73%) 
Diabetes 
 
1 (2%) 6 (14%) † 3 (20%) 1 (7%) 
Dyslipidaemia  
 
19 (37%)     30 (70%) † 
 
7 (47%) 12 (80%) 
CHD  5 (10%)     18 (42%) † 
 
5 (33%) 4 (27%) 
Medication 
 
    
Anti-hypertensive 
agents: 
    Beta blockers  
    AT II receptor  
    antagonists 
    ACE inhibitors   
    Ca2+ channel 
    blockers 








































4 (8%) 25 (58%) † 11 (73%) 7 (47%) 
NSAIDs 
 
4 (8%) 6 (14%) 1 (7%) 2 (13%) 
Statins 
 
18 (35%) 32 (74%) † 8 (53%) ‡ 13 (87%) 
† AAA significantly different to control (Fisher’s exact test, p<0.05) 
* AAA significantly different to control (Student’s t-test) 
‡ AAA omega cohort significantly different to placebo cohort (Fisher’s exact test, p<0.05) 
BMI, body mass index; CHD, coronary heart disease; AT II, angiotensin II; Ca2+, calcium; NSAIDs, 
non-steroidal anti-inflammatory drugs; SBP, systolic blood pressure; DBP, diastolic blood pressure










Table 2: Erythrocyte fatty acid profiles of control participants and AAA patients 
(mean%±SEM) 
Fatty Acid Control AAA 
Saturated fatty acids   
C14:0 0.46±0.03 0.61±0.06 
C15:0 0.17±0.01 0.26±0.04 
C16:0 24.03±0.24 23.40±0.22 
C17:0 0.28±0.01 0.34±0.01** 
C18:0 14.23±0.13 14.23±0.13 
C20:0 0.42±0.05 0.46±0.01 
C22:0 3.16±0.14 3.17±0.14 
Monounsaturated fatty acids   
C16:1n7 0.37±0.03 0.48±0.04 
C18:1n-9 14.56±0.20 14.44±0.23 
Trans fatty acids   
C18:1t 1.31±0.03 1.42±0.04 
n-6 Polyunsaturated fatty acids  
C18:2 9.27±0.21 7.57±0.17** 
C18:3 0.05±0.003 0.06±0.003 
C20:2 0.15±0.01 0.16±0.01 
C20:3 1.28±0.04 1.34±0.05 
C20:4 12.52±0.18 12.89±0.22 
C22:4 1.80±0.06 2.05±0.07 
n-3 Polyunsaturated fatty acids  
C20:5 0.94±0.05 0.98±0.05 
C22:5 1.84±0.03 1.96±0.05*** 
C22:6 3.13±0.10 3.46±0.11 
Very long chain fatty acids   
C24:0 4.56±0.09 5.05±0.11 
C24:1n9 4.70±0.10 5.27±0.1 
C23:0 0.22±0.01 0.24±0.01 
Other fatty acids   
C20:1n-7 0.18±0.01 0.16±0.01 
Ratio n-6/n-3 4.08±0.13 3.61±0.11* 
n-3 Index 4.07±0.13 4.42±0.12 
* AAA significantly different to control (* p<0.05; ** p<0.01; *** p<0.001) 
Data was adjusted for hypertension, diabetes mellitus, coronary heart disease, low- 
dose aspirin and statin use, active or previous smoking history and age. 










Table 3: Erythrocyte fatty acid ratios as indices of enzyme activities in control  
participants and AAA patients (Mean±SEM) 









(Oleic acid/stearic acid) 
1.03±0.02 1.02±0.02 






LA → AA biosynthesis 
(AA/LA) 
1.37±0.06 1.75±0.06** 
Stearoyl-CoA desaturase  
(Palmitoleic acid/palmitic acid) 
0.015±0.001 0.02±0.002 
Elongase 2/5 
(Adrenic acid/AA)  
0.14±0.005 0.16±0.03 
* AAA significantly different to control (* p<0.05; ** p<0.01, *** p<0.001) 
Data was adjusted for hypertension, diabetes mellitus, coronary heart disease, low-dose aspirin  













































Table 4: Red blood cell indices, white blood cell counts and platelet counts and  
indices for control participants and AAA patients (mean±SEM) 
Blood Parameter Control AAA 
WBC (x109/L) 6.1±0.2 6.7±0.3 
Lymphocytes (x109/L) 1.9±0.1 2.1±0.1 
Monocytes (x109/L) 0.4±0.02 0.4±0.1 
Granulocytes (x109/L) 3.8±0.2 4.2±0.2 
RBC (x1012/L) 4.7±0.1 4.8±0.1 
Hgb (g/L) 142.2±2.3 143.1±2.6 
Hct (%) 43.5±0.6 43.7±0.7 
MCV (fL) 91.8±0.8 92.1±0.7 
MCH (pg) 30.0±0.3 30.1±0.3 
MCHC (g/L) 326.9±1.5 327.2±1.8 
RDW (%) 13.9±0.2 14.7±0.3 
Platelet (x109/L) 240.6±10.8 199.9±10.8 
MPV (fL) 7.8±0.2 8.0±0.2 
Pct (%) 0.19±0.01 0.16±0.01 
PDW 17.1±0.1 17.0±0.2 
* AAA significantly different to control (* p<0.05); WBC, white blood cells; RBC, red blood cells;  
Hgb, haemoglobin; Hct, haematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular  
haemoglobin; MCHC, mean corpuscular haemoglobin concentration; RDW, red blood cell  
distribution width; MPV, mean plateletvolume; Pct, plateletcrit; PDW, platelet distribution width;  
Data was adjusted for hypertension, diabetes mellitus, coronary heart disease, low-dose aspirin  
and statin use, active or previous smoking history and age 
  










Table 5: Erythrocyte fatty acid profiles of AAA patients (mean%±SEM). 
 
Fatty Acid 
AAA, Fish Oil Cohort AAA, Placebo Cohort 
Baseline Week 3 Week 12 Baseline Week 3 Week 12 
Saturated fatty acids    
C14:0 0.71±0.12 0.71±0.06 0.51±0.06 0.73±0.09 0.67±0.08 0.58±0.06 
C15:0 0.36±0.08 0.39±0.08 0.24±0.05 0.29±0.07 0.44±0.12 0.18±0.01 
C16:0 22.71±0.22 23.65±0.32 23.49±0.36 22.63±0.30 22.73±0.23 23.22±0.43 
C17:0 0.35±0.01 0.36±0.02 0.36±0.03 0.39±0.02 0.37±0.02 0.34±0.02 
C18:0 14.15±0.25 14.39±0.25 14.98±0.43 14.44±0.23 14.08±0.22 14.62±0.26 
C20:0 0.46±0.02 0.48±0.09 0.65±0.13 0.51±0.02 0.49±0.03 0.59±0.11 
C22:0 3.27±0.28 2.69±0.29 2.98±0.28 3.04±0.28 3.02±0.31 3.20±0.25 
Monounsaturated fatty acids    
C16:1n7 0.58±0.10 0.56±0.07 0.54±0.09 0.51±0.06 0.56±0.07 0.52±0.07 
C18:1n-9 14.03±0.32 13.94±0.25 14.46±0.38 13.79±0.30 14.15±0.41 14.31±0.41 
Trans fatty acids    
C18:1t 1.40±0.08 1.38±0.08 1.70±0.21 1.41±0.07 1.38±0.05 1.56±0.13 
n-6 Polyunsaturated fatty acids    
C18:2 7.57±0.26 7.55±0.33 7.43±0.29 7.60±0.31 8.21±0.36 7.39±0.21 
C18:3 0.06±0.005 0.09±0.04 0.05±0.01 0.06±0.005 0.06±0.004 0.05±0.01 
C20:2 0.17±0.02 0.17±0.02 0.14±0.01 0.18±0.01 0.19±0.02 0.25±0.11 
C20:3 1.32±0.05 1.14±0.05† 1.04±0.06† 1.51±0.08 1.52±0.09§§§ 1.38±0.09§§ 
C20:4 12.46±0.23 11.72±0.22† 10.14±0.3††† 13.09±0.38 12.57±0.40 12.81±0.41§§§ 










C22:4 2.12±0.13 1.92±0.12 1.23±0.09††† 2.09±0.09 2.02±0.12 2.05±0.12§§§ 
n-3 Polyunsaturated fatty acids    
C20:5 0.99±0.07 1.35±0.06†† 1.72±0.11††† 0.89±0.06 0.91±0.08§§§ 0.95±0.09§§§ 
C22:5 1.97±0.09 1.87±0.08 1.61±0.08† 2.03±0.09 1.94±0.09 1.89±0.10 
C22:6 3.54±0.22 4.72±0.19†† 6.21±0.20††† 3.48±0.17 3.53±0.21§§§ 3.31±0.24§§§ 
Very long chain fatty acids    
C24:0 5.25±0.19 5.04±0.17 4.92±0.24 5.44±0.12 5.34±0.16 5.23±0.20 
C24:1n9 5.67±0.14 5.51±0.16 4.93±0.2††† 5.42±0.12 5.38±0.17 5.11±0.22 
C23:0 0.24±0.02 0.26±0.01 0.24±0.02 0.28±0.01 0.29±0.01 0.25±0.02 
Other fatty acids    
C20:1n-7 0.13±0.02 0.14±0.02 0.16±0.02 0.17±0.02 0.14±0.02 0.21±0.01§ 
Ratio n-6/n-3 3.48±0.16 2.69±0.08††† 2.00±0.08††† 3.66±0.20 3.68±0.22§§§ 3.73±0.21§§§ 
n-3 Index 4.53±0.22 6.07±0.19††† 8.03±0.20††† 4.37±0.20 4.43±0.25§§§ 4.26±0.28§§§ 
† Fish oil cohort week 3/week 12 significantly different to fish oil cohort baseline († p<0.05; †† p<0.01; ††† p<0.001) 
















Table 6: Erythrocyte fatty acid ratios as indices of enzyme activities in AAA patients (Mean±SEM) 
 
Index of enzyme activity 
Fish oil cohort 
Baseline                         Week 3                           Week 12 
Δ-4 desaturase 
(DHA/DPA) 
1.85±0.14 2.60±0.16†† 3.93±0.17††† 
Δ-9 desaturase 
(Oleic acid/stearic acid) 
1.00±0.03 0.97±0.03 0.98±0.04 
Δ-6 desaturase (1) 
Dihomo-γ-linolenic/linoleic 
0.18±0.01 0.15±0.01 0.15±0.01 
Δ-desaturase (2) 
γ-Linolenic/linoleic 
0.01±0.001 0.01±0.001 0.01±0.001 
LA → AA biosynthesis 
(AA/LA) 
1.68±0.08 1.60±0.09 1.40±0.07† 
Stearoyl-CoA desaturase  
(Palmitoleic acid/palmitic 
acid) 
0.03±0.004 0.02±0.003 0.02±0.003 
Elongase 2/5 
(Adrenic acid/AA)  
0.17±0.01 0.16±0.01 0.12±0.01†† 



















Fish Oil Cohort Placebo Cohort 
Baseline Week 3 Week 12 Baseline Week 3 Week 12 
WBC (x109/L) 6.9±0.5 6.3±0.5 6.6±0.4 6.6±0.5 6.5±0.4 6.7±0.5 
Lymphocytes 
  (x109/L) 
2.1±0.1 2.0±0.2 2.1±0.2 2.1±0.2 1.8±0.2 1.9±0.2 
  Monocytes 
  (x109/L) 
0.4±0.1 0.4±0.1 0.4±0.1 0.4±0.05 0.3±0.02 0.5±0.1 
Granulocytes 
  (x109/L) 
4.4±0.4 3.8±0.3 4.0±0.3 4.1±0.3 4.3±0.3 4.4±0.4 
RBC (x1012/L) 4.7±0.1 4.6±0.1 4.6±0.1† 4.8±0.1 4.7±0.1 4.8±0.2 
  Hgb (g/L) 144.1±3.5 142.5±4.0 139.2±3.6 143.8±3.9 142.2±4.5 143.7±5.1 
  Hct (%) 44.1±1.0 43.5±1.1 42.5±1.1† 43.7±1.1 43.5±1.3 43.8±1.5 
  MCV (fL) 93.5±0.9 94.6±1.2 93.6±1.2 91.0±0.9 91.8±1.0 91.9±1.2 
  MCH (pg) 30.5±0.3 31.0±0.5 30.7±0.5 30.0±0.4 30.0±0.4 30.2±0.6 
  MCHC (g/L) 326.6±2.8 327.1±3.2 328.3±2.2 328.8±2.4 326.6±1.9 328.0±2.3 
  RDW (%) 14.8±0.4 14.5±0.4 13.8±0.2†† 14.4±0.3 14.7±0.3 14.0±0.2 
Platelet 
(x109/L) 
207.9±16.0 205.5±21.1 198.3±14.1† 192.8±16.3 194.4±19.2 191.3±24.1 
  MPV (fL) 8.0±0.3 7.5±0.4 7.7±0.2 7.7±0.2 7.8±0.2 8.0±0.2 
  Pct (%) 0.17±0.01 0.15±0.02 0.15±0.01† 0.15±0.01 0.15±0.02 0.15±0.02 
  PDW 16.8±0.2 17.0±0.2 16.9±0.2 17.3±0.2 17.0±0.3 17.3±0.3 
† Fish oil cohort week 3/week 12 significantly different to fish oil cohort baseline († p<0.05; †† p<0.01); WBC, white 
blood cells; RBC, red blood cells; Hgb, haemoglobin; Hct, haematocrit; MCV, mean corpuscular volume; MCH, mean 
corpuscular haemoglobin; MCHC, mean corpuscular haemoglobin concentration; RDW, red blood cell distribution 






















Table 8:  Independent associations between AAA diagnosis and assessed variables using multi-variable 
regression analysis 
Variable 𝛃 Standard Error 95% CI P value 
Margaric acid 0.509 0.029 0.025-0.144 0.007 
Linoleic acid -0.522 0.541 -2.640-(-0.446) 0.007 
Docosapentaenoic acid 0.715 0.115 0.260-0.725 <0.001 
∆6-Desaturase (1) 0.538 0.018 0.017-0.089 0.005 
LA →AA biosynthesis 0.516 0.143 0.110-0.689 0.008 
n-6/n-3 Ratio -0.403 0.334 -1.1364-(-0.010) 0.047 
Data was adjusted for hypertension, diabetes mellitus, coronary heart disease, low-dose aspirin and statin use, active or 
previous smoking history and age. 95% CI, 95% Confidence interval. No independent associations were observed for 
red blood cell distribution width, omega-3 index, adrenic acid, arachidonic acid (AA), myristic acid, pentadecanoic 
acid, palmitoleic acid, elaidic acid, γ-linolenic acid, DHA, lignoceric acid, nervonic acid, tricosanoic acid, stearoyl-




Figure 1: Study flowchart.  The intervention study included 32 AAA patients, 30 of which completed the 
protocol. 
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